Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 10/20 | 0.56 |
| ▸ | RAF1 | P04049 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878393 | 1.00 | NPC1 (0.56) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL4241513 | 0.90 | HDAC4 (0.54) | BRAFRAF1 | |
| SCHEMBL26165525 | 0.89 | RAB9A (0.60) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL30017275 | 0.85 | NPC1 (0.56) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL21624459 | 0.85 | NPC1 (0.56) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL23482203 | 0.85 | NPC1 (0.56) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL30405369 | 0.85 | NPC1 (0.56) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL29071543 | 0.84 | RAF1 (0.57) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL26075563 | 0.84 | LMNA (0.62) | NPC1LMNARAB9ASMN1; SMN2BRAF | |
| SCHEMBL29877984 | 0.84 | RAF1 (0.58) | NPC1LMNARAB9ASMN1; SMN2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | NPC1 4064/4885LMNA 4752/4885RAB9A 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.